TriangleLerapolturev (NCT06177964)
Lerapolturev trial for Recurrent Supratentorial Glioblastoma (NCT06177964). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent supratentorial glioblastoma undergoing surgery. Prior radiation is required; prior chemotherapy depends on MGMT status. Lerapolturev recipients need polio vaccination and a booster.
The idea: lerapolturev is a modified virus designed to infect tumor cells and stimulate immunity. A safety stage tests two tumor infusions four days apart. The randomized stage adds repeated injections near neck lymph nodes, versus oral lomustine every six weeks. Researchers assess safety and survival.
This phase 2 study plans 92 patients. Madison Shoaf leads at Duke, Durham, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.